SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Co.'s Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the U.S. for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. Co. also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. The SWTX average annual return since 2019 is shown above.
The Average Annual Return on the SWTX average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SWTX average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SWTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free SWTX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
